Axonics Modulation Technologies raises $130 million via public offering

GIlde Healthcare

Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that is commercializing novel implantable rechargeable sacral neuromodulation devices (r-SNM Systems) for the treatment of bladder and bowel dysfunction, announced the pricing of its public offering of 4,000,000 shares of its common stock at a public offering price of $32.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics are expected to be $130 million. In addition, the underwriters have a 30-day option to purchase up to an additional 600,000 shares. BofA Securities, Morgan Stanley and Wells Fargo Securities are acting as the joint book-running managers for the offering and representatives of the underwriters. SVB Leerink and Needham & Company are acting as co-managers for the offering.

Axonics anticipates using net proceeds from the offering to support the commercialization of its r-SNM System in the United States, Europe and Canada. Via its r-SNM Systems, Axonics enables improved care at affordable cost for millions of patients worldwide suffering from incontinence, reflecting Gilde Healthcare’s patient centric investment strategy.

About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction.
For more information, visit the company’s website at www.axonics.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.
For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Vapotherm raises $87 million via public offering

GIlde Healthcare

Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the pricing of an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26.00 per share. The gross proceeds from the offering to Vapotherm are expected to be $87 million. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares. BofA Securities and William Blair are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager and BTIG is acting as co-manager.
Vapotherm intends to use the net proceeds from this offering to hire additional sales and marketing personnel and expand marketing programs both in the United States and internationally. Hi-VNI Technology is mask-free noninvasive ventilatory support for spontaneously breathing patients and is a front-line tool for relieving respiratory distress — including COVID-related. Vapotherm enables improved care at affordable cost for millions of patients worldwide suffering from respiratory distress, reflecting Gilde Healthcare’s patient centric investment strategy.

About Vapotherm

Vapotherm, Inc. is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.2 million patients have been treated with Vapotherm Hi-VNI Technology. Hi-VNI Technology is mask-free noninvasive ventilatory support for spontaneously breathing patients and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. Hi-VNI Technology’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.
For more information, visit the company’s website at www.vapotherm.com.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.
For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Onex to Acquire Independent Clinical Services

No Comments

Onex

Toronto, April 16, 2020 – Onex Corporation (“Onex”) (TSX: ONEX) and its affiliated funds
today announced that it has agreed to acquire Independent Clinical Services Group Ltd. (“ICS”)
in partnership with the existing management team and with a reinvestment in the equity by the
former majority shareholder, TowerBrook Capital Partners LP. ICS is a leading specialised
staffing, workforce management solutions, and health and social services business operating
primarily in Europe and present across four continents globally. ICS’s 1,850 employees serve
over 2,000 clients from offices in 10 countries. The transaction is expected to close later this
year, subject to customary conditions and regulatory approvals. The terms of the transaction are
not being disclosed.

“ICS is committed to being a true partner to its clients in delivering both capacity and care at the
highest standard, and that is a commitment we want to continue and build on,” said Nigel
Wright, a Managing Director with Onex. “We are pleased to be partnering with the ICS
management team and look forward to supporting their growth for years to come.”
“Onex’ strong investment track record and history of supporting the teams it invests alongside
makes it an ideal partner for us,” said Mike Barnard, Chief Executive Officer of ICS. “Our first
priority is to provide high-quality healthcare staffing and services to our clients and partners
around the world. Onex is aligned with the strategic direction of our firm and we are excited to
work together in our next phase of growth.”
The investment will be made by Onex Partners V, Onex’ $7.2 billion fund.

About Onex
Founded in 1984, Onex invests and manages capital on behalf of its shareholders, institutional
investors and high net worth clients from around the world. Onex’ platforms include: Onex
Partners, private equity funds focused on larger opportunities in North America and Europe;
ONCAP, private equity funds focused on middle market and smaller opportunities in North
America; Onex Credit, which manages primarily non-investment grade debt through
collateralized loan obligations, private debt and other credit strategies; and Gluskin Sheff’s
actively managed public equity and public credit funds. In total, Onex has approximately
$38.4 billion of assets under management, of which approximately $7.2 billion is its own
shareholder capital. With offices in Toronto, New York, New Jersey and London, Onex and its
experienced management teams are collectively the largest investors across Onex’ platforms.
The Onex Partners and ONCAP businesses have assets of $42 billion, generate annual revenues
of $28 billion and employ approximately 171,000 people worldwide. Onex shares trade on the
Toronto Stock Exchange under the stock symbol ONEX.

For more information on Onex, visit
its website at www.onex.com. Onex’ security filings can also be accessed at www.sedar.com.
This news release may contain forward-looking statements that are based on management’s
current expectations and are subject to known and unknown uncertainties and risks, which could
cause actual results to differ materially from those contemplated or implied by such
forward-looking statements. Onex is under no obligation to update any forward-looking
statements contained herein should material facts change due to new information, future events
or otherwise.

For further information:
Claire Glossop Irani
Director, Client and Product Solutions
416.362.7711

 

Categories: News

Tags:

Yellowtail now part of conclusion ecosystem

No Comments

NPM Capital

Conclusion has integrated Yellowtail into its ecosystem. With this, the IT service provider strengthens its position in the financial sector and in the field of digital transformations. Yellowtail is a leading fintech label in the Netherlands focusing on pension funds, banks and insurers. Yellowtail designs, builds and manages digital and data-driven software solutions for financial service providers, with the mission to improve the quality of consumers’ financial lives.

Yellowtail combines expertise of the financial market, IT and User Experience with innovative capacity and implementation power to develop innovative original solutions such as MyLife, Mortgage Assist and MyMortgage. Through these smart digital and data-driven software solutions, Yellowtail brings financial service providers closer to their customers, they can activate these customers better and provide them with advice that suits their financial situation. This gives consumers more direction to their financial future with relative ease.

The Key Control Dashboard platform with a strong position within central and local government is also part of the Yellowtail portfolio. The Key Control Dashboard offers an integrated approach to governance, risk and control in order to allow organizations to be demonstrably “in control” and to comply with the relevant standards frameworks (BIO, ISO27001, NEN7510) and legislation (AVG).

Matthijs Mons, managing director of Yellowtail: “As part of Conclusion, Yellowtail can really take the next step. We see multiple opportunities by working with Conclusion labels that better position us together with large accounts within the ecosystem and get more strength to take on large projects.” Yellowtail’s other managing directors, Robin Bouman, Edwin Lodder and Mark Leck, add: “With our domain knowledge and data driven expertise, Yellowtail contributes to the power of Conclusion as a digital transformation player.”

Engbert Verkoren, CEO at Conclusion (a participation of NPM Capital): “The fact that Yellowtail is now part of the ecosystem strengthens us as a transformation partner in the financial sector. A sustainable and personal customer relationship will become crucial for financial institutions in the coming years. With Yellowtail’s data-driven software solutions, we can help financial service providers in this (digital) transformation.”

Also read ‘IT service provider Conclusion number 1 in the Netherlands’
Also read ‘KWD Resultaatmanagment now part of Conclusion ecosysteem’

Navamedic enters into distribution agreement for ThermaCare®

Reiten

Navamedic recently announced that they have entered into an exclusive distribution agreement with Angelini Pharma for ThermaCare® in the Nordics and the strategically important Dutch market. With the agreement, Navamedic strengthens its position in the Consumer Health segment and enters the important pain category.

ThermaCare® was launched by Procter & Gamble in 2001 and is an advanced pain therapy for back, neck and muscles, classified as a Medical Device class IIa. The therapy is applied as heat wraps which is activated upon contact with air and placed on pain points, exactly where the user needs it. ThermaCare® delivers up to 16 hours of pain relief, 8 hours while used and 8 hours after it has been taken off. The larger adhesive area makes it easy to re-adjust, and the single-use wraps are thin enough to be worn discreetly under clothing.

Angelina Pharma is a part of the Italian Angelini Group and they acquired the ThermaCare® global business rights (excluding North America) from GSK earlier this year. In the distribution agreement now entered into with Angelina Pharma, Navamedic will take over and accelerate marketing, sales and distribution of ThermaCare® in the Nordics and Netherlands from July 2020. The agreement has a duration of eight years, with options to extend.

For further info, please see company press release: http://www.navamedic.com/no/nyheter/2020/03/navamedic-asa-enters-into-distribution-agreement-for-thermacare-with-angelini-pharma/

 

Categories: News

Tags:

JenaValve Technology Closes $50 Million Financing

GIMV

Equity Round led by Bain Capital Life Sciences

IRVINE, Calif. (February 5, 2020) – JenaValve Technology, Inc., developer and manufacturer of the
JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of
aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital
Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv,
Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. The Company
also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the
JenaValve Board of Directors.

“We are pleased to complete this financing led by new investor Bain Capital Life Sciences, a wellrespected name in healthcare, as well as strong participation from our existing venture investors,” said John Kilcoyne, JenaValve’s Chief Executive Officer. “This announcement comes on the heels of receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which
allows for priority review of our Align Clinical Trial for the treatment of symptomatic, severe aortic
regurgitation (AR) and AR-dominant mixed aortic valve disease. Our TAVR system is differentiated in
that no other transcatheter valve device has FDA approval for patients suffering from severe AR who are
at high risk for surgery, which we believe is a multi-billion-dollar market opportunity. This financing
supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE)
approval in the second half of 2020.”

JenaValve is conducting a global multicenter clinical program for the treatment of patients with severe
AR and AR-dominant mixed aortic valve disease who are at high risk for surgery. Following completion
of the HDE portion of the trial, patient enrollment will continue in support of submitting a Premarket
Approval (PMA) application to the FDA under the Breakthrough Device program. The Company also
anticipates filing the JenaValve® for CE mark approval for both aortic stenosis and aortic regurgitation in
the second half of 2020.
“We welcome Dr. Hack to our Board and look forward to Bain Capital’s contribution to governance and
strategy,” added Mr. Kilcoyne. “Andrew’s industry knowledge and experience, as well as his success as
an institutional investor and chief financial officer will add valuable perspectives to our Board.”
Dr. Hack commented, “I’m delighted to join the JenaValve Board as the Company works to gain approval
for a solution to a significant unmet medical need. JenaValve’s focus on advancing a breakthrough
technology with the ability to improve patient lives embodies the characteristics we seek at Bain Capital
Life Sciences. We are committed to providing both financial assistance and oversight in support of
JenaValve’s success.”

Dr. Hack has served as a Managing Director at Bain Capital Life Sciences since 2019. He previously
served as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio
manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcare focused hedge funds and investment banks. Dr. Hack received an MD and a PhD in molecular genetics
and cell biology from the University of Chicago.

About the JenaValve Transfemoral TAVR System
The JenaValve Pericardial TAVR System consists of a bioprosthesis comprised of a self-expanding nitinol
stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques.
The TAVR System is available in three sizes to treat a broad range of aortic annulus diameters.
The JenaValve Pericardial TAVR System is an investigational device, and is not available for sale in the
United States or internationally.

About Bain Capital Life Sciences
Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical,
specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies
globally. The team focuses on companies that both drive medical innovation across the value chain and
enable that innovation to improve the lives of patients with unmet medical needs. Since 1984, Bain
Capital has developed global reach, deep expertise and a proven track record in life sciences industries
across its Private Equity, Credit, Public Equity and Venture business units. Bain Capital Life Sciences
builds on the differentiated skillset and enables the firm to pursue opportunities created by several longterm trends in healthcare.

About JenaValve
JenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops
and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from
aortic valve disease. The Company is in clinical development of its next-generation transfemoral TAVR
system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic
regurgitation. In addition to Bain Capital Life Sciences, JenaValve is backed by European and Asian
investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv
(Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI
Partners. Additional information is available at www.jenavalve.com.
###
Investor and Media Contact:
Matt Clawson
W2Opure
(949) 370-8500
mclawson@w2ogroup.com

Categories: News

Tags:

JenaValve Technology Closes $50 Million Financing

GIMV

IRVINE, Calif. (February 5, 2020) – JenaValve Technology, Inc., developer and manufacturer of the
JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of
aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital
Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv,
Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. The Company
also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the
JenaValve Board of Directors.

“We are pleased to complete this financing led by new investor Bain Capital Life Sciences, a wellrespected name in healthcare, as well as strong participation from our existing venture investors,” said John Kilcoyne, JenaValve’s Chief Executive Officer. “This announcement comes on the heels of receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA), which
allows for priority review of our Align Clinical Trial for the treatment of symptomatic, severe aortic
regurgitation (AR) and AR-dominant mixed aortic valve disease. Our TAVR system is differentiated in
that no other transcatheter valve device has FDA approval for patients suffering from severe AR who are
at high risk for surgery, which we believe is a multi-billion-dollar market opportunity. This financing
supports our ongoing clinical program and plans to file for U.S. Humanitarian Device Exemption (HDE)
approval in the second half of 2020.”

JenaValve is conducting a global multicenter clinical program for the treatment of patients with severe
AR and AR-dominant mixed aortic valve disease who are at high risk for surgery. Following completion
of the HDE portion of the trial, patient enrollment will continue in support of submitting a Premarket
Approval (PMA) application to the FDA under the Breakthrough Device program. The Company also
anticipates filing the JenaValve® for CE mark approval for both aortic stenosis and aortic regurgitation in
the second half of 2020.

“We welcome Dr. Hack to our Board and look forward to Bain Capital’s contribution to governance and
strategy,” added Mr. Kilcoyne. “Andrew’s industry knowledge and experience, as well as his success as
an institutional investor and chief financial officer will add valuable perspectives to our Board.”
Dr. Hack commented, “I’m delighted to join the JenaValve Board as the Company works to gain approval
for a solution to a significant unmet medical need. JenaValve’s focus on advancing a breakthrough
technology with the ability to improve patient lives embodies the characteristics we seek at Bain Capital
Life Sciences. We are committed to providing both financial assistance and oversight in support of
JenaValve’s success.”

Dr. Hack has served as a Managing Director at Bain Capital Life Sciences since 2019. He previously
served as Chief Financial Officer of Editas Medicine (Nasdaq: EDIT) and as a healthcare portfolio
manager at Millennium Management. Prior to that, he was a securities analyst at a number of healthcarefocused hedge funds and investment banks. Dr. Hack received an MD and a PhD in molecular genetics
and cell biology from the University of Chicago.

About the JenaValve Transfemoral TAVR System
The JenaValve Pericardial TAVR System consists of a bioprosthesis comprised of a self-expanding nitinol
stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques.
The TAVR System is available in three sizes to treat a broad range of aortic annulus diameters.
The JenaValve Pericardial TAVR System is an investigational device, and is not available for sale in the
United States or internationally.

About Bain Capital Life Sciences
Bain Capital Life Sciences (www.baincapitallifesciences.com) pursues investments in biopharmaceutical,
specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies
globally. The team focuses on companies that both drive medical innovation across the value chain and
enable that innovation to improve the lives of patients with unmet medical needs. Since 1984, Bain
Capital has developed global reach, deep expertise and a proven track record in life sciences industries
across its Private Equity, Credit, Public Equity and Venture business units. Bain Capital Life Sciences
builds on the differentiated skillset and enables the firm to pursue opportunities created by several longterm trends in healthcare.

About JenaValve
JenaValve Technology, Inc., with locations in Irvine, Calif., Leeds, U.K. and Munich, Germany, develops
and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from
aortic valve disease. The Company is in clinical development of its next-generation transfemoral TAVR
system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic
regurgitation. In addition to Bain Capital Life Sciences, JenaValve is backed by European and Asian
investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv
(Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI
Partners. Additional information is available at www.jenavalve.com.

Investor and Media Contact:
Matt Clawson
W2Opure
(949) 370-8500
mclawson@w2ogroup.com

Categories: News

Tags:

Hg invests in Intelerad Medical Systems, accelerating growth of best-in-class enterprise medical imaging solutions provider

HG Capital

  • Transaction will reinforce Hg’s focus on healthcare technology, with over $1bn invested to date in the sector globally;
  • Intelerad will look to use this new investment and expertise to maximize client business and health outcomes through innovation and operational excellence.

London, U.K. and Montreal, Canada, 23 January 2020

Hg, the specialist private equity investor focused on software and service businesses, today announces that it has finalized an agreement for an investment in Intelerad Medical Systems™ (“Intelerad”), a leading global provider of medical imaging software and enterprise workflow solutions. The terms of the transaction are not disclosed. The transaction is expected to close in the first quarter of 2020, following satisfaction of customary regulatory approvals.

Founded in 1999, Intelerad is a medical imaging software provider that specialises in diagnostic viewing, reporting and collaboration solutions for radiologists. Headquartered in Montreal (CA), Intelerad has over 400 employees located in various offices in Canada, the United States, the United Kingdom, and Australia. The company serves over 300 healthcare organizations around the world, including radiology groups, imaging centers, clinics and reading groups, and has a strong and growing presence in hospital imaging departments. Intelerad was awarded Best in KLAS recognitions, ranking #1 for PACS Canada and #1 for PACS Asia/Oceania in the 2019 Best in KLAS: Global Software (Non-US) report.

Hg recognizes Intelerad’s leading role in supporting radiologists globally to deliver highly accurate diagnoses at optimum productivity. The business is a key enabler of healthcare delivery against a backdrop of increasing global demands, in radiology, for scalable and more efficient imaging, data management and workflow solutions. Intelerad is led by a highly-talented team who have developed powerful solutions for radiologists, offering both efficiency and a premium service that helps create superior outcomes for both patients and healthcare providers.

Healthcare technology is a core sector for Hg, with an investment focus on healthcare operations, core systems, life sciences digitization, interoperability and population health. Intelerad represents the 5th healthcare technology investment in Hg’s current portfolio, joining Rhapsody + Corepoint, a global leader in healthcare interoperability and data liquidity solutions; Allocate Software, a global provider of healthcare workforce and risk management software; Evaluate, which supplies mission-critical commercial information to the pharmaceutical industry globally; and Medifox, which provides software solutions to ambulatory care services, elderly care homes and therapists.

Hg’s investment will be made from the Hg Genesis 8 Fund and represents the firm’s first investment in Canada and second investment led by the New York office, since opening in 2019. The Hg team was led by Gero Wittemann, Hector Guinness, J-B Brian and David Issott.

Under the terms of the agreement, Hg will acquire Intelerad from Novacap’s TMT IV Fund, and its founders, management and employee shareholders who will all be re-investing into the business alongside Hg.

Paul Lepage, Chief Executive Officer at Intelerad, said:

“Partnering with Hg gives us access to a huge pool of knowledge in global healthcare technology and the opportunity to significantly advance the company’s strategy. We are thrilled to continue making a difference in healthcare with such talented people. As well as welcoming our new investors, I also thank the Novacap team and our colleagues who all worked so hard to get us into this strong position, as well as our customers for their continued trust over the last 20 years. Looking forward to exciting times ahead.”

Gero Wittemann, Partner and co-lead of Hg’s New York team, commented:

“Intelerad has a winning platform that creates significant efficiencies for healthcare organizations, while adding true value to help radiologists and other physicians view, interpret and share medical images. We fully embrace Intelerad’s vision in making a sustainable difference in healthcare and it’s particularly exciting to join Paul and the team at this stage in the company’s journey. We will look to leverage our experience in healthcare technology and our operational experts to support the business strategy through innovation and operational excellence.”

Hg were advised on the investment by Tripletree, Bain, Marwood, EY and White & Case.

Categories: News

Tags:

Telemos Capital secures financing for Medeuropa, a leading european cancer care group

Telemos Capital

21.01.2020–Telemos Capital (“Telemos”) announces that its portfolio company MedEuropa, a leading European cancer care group, has successfully secured debt financing from Ardian. The senior facilities have been partially utilised as acquisition financing of MedEuropa’s first French acquisition and will continue to be used to support the company’s exciting buy-and-build strategy.

The financing is reflective of the strength of MedEuropa’s proposition and ability to execute on the organic and inorganic growth opportunities within the European cancer care market,with three radiotherapy centres already acquired since establishment.

Nils Hagerståland Dipesh Mahtani of Telemos said: “We are delighted to have secured debt financing for MedEuropa, which reinforces the strength of the strategy and execution capabilities of the management team. Ardian have shown themselves to be ideal partners to flexibly support MedEuropa as it pursues its ambitious buy-and-build strategy.

”Ralph Hefti, MedEuropa’s CEO, commented: “Ardian’s ability to offer a flexible solution to the Group’s requirements was key to this partnership. Ardian has been extremely responsive and creative and has set up financing that is very well suited to the way MedEuropa intends to move forward.”

Guillaume Chinardet, Head of Ardian Private Debt France, said: “We look forward to the long term cooperation with the MedEuropa management team and Telemos Capital, valuable partners with strong expertise in the European healthcare services market. We are convinced that MedEuropa will achieve further growth via strategic acquisitions in the fragmented European radiotherapy market.”

Press Contacts Telemos Capitalinfo@telemoscapital.com+44 (0)20 3906 6820

About MedEuropa

Founded in 2017, MedEuropa is committed to providing state of the art cancer treatment across Europe, with a strong focus on radiotherapy. MedEuropa seeks to partner with leading medical professionals, who share its vision of improving the provision and quality of cancer treatment. MedEuropa is pursuing an ambitious buy and build strategy, focusing on new partnership and acquisition opportunities across Europe.

Please visit www.medeuropa.org for more information.

About Telemos Capital

Telemos Capital, a London based investment firm founded in 2017,invests in private European businesses, with the aim of building great companies for the long term. Funded by family capital, it combines the flexibility and nimble decision-making of a family office with the active ownership and professionalism of private equity. Telemos looks to deploy €50m-€200m of equity per investment and seeks to acquire majority stakes in businesses with the potential for sustainable growth through international expansion, add-on acquisitions or operational improvements.

Please visit www.telemoscapital.com for more information.

 

Categories: News

Tags:

Ardian arranges a senior financing for Telemos Capital and Medeuropa’s acquisition of CCO Perpignan

Ardian

Paris, January 21st, 2020 – Ardian, a world leading private investment house, today announces the arrangement of a senior financing facility to support Telemos Capital and MedEuropa’s acquisition of CCO Perpignan. The financing package also includes a committed acquisition facility to finance future build-ups.

MedEuropa is a European cancer care company with a strong focus on radiotherapy. Radiotherapy is one of the most commonly used therapies for cancer treatment and consists in the use of high doses of radiation to eliminate cancer cells and shrink tumors. It can be used as a standalone oncology treatment or in combination with other cancer treatments such as surgery or chemotherapy.

Headquartered in Switzerland, the MedEuropa platform was founded in 2017 by Telemos Capital. The network was initially created through the acquisition of two radiotherapy centers in Germany in January 2019 (Krefeld and Hannover, the leading providers of Gamma Knife treatments, a specialized application of radiotherapy for complex brain tumors) and is to be further enlarged through the acquisition of CCO Perpignan, a radiotherapy center in the South of France.

The combination of all three entities will form a Group operating a total of six treatment machines treating a total c. 2,900 patients per year. As has been the case with the German acquisitions, MedEuropa will continue to partner with the CCO Perpignan doctors, ensuring continuity of high-quality care for patients and referring physicians.

Guillaume Chinardet, Head of Ardian Private Debt France, said: “We look forward to the long term cooperation with the MedEuropa management team and Telemos Capital, valuable partners with strong expertise in the European healthcare services market. We are convinced that MedEuropa will achieve further growth via strategic acquisitions in the fragmented European radiotherapy market.”

Jean-David Ponsin, Managing Director at Ardian Private Debt, further added: ”We are pleased to support the Group in this new chapter of its growth journey and we are convinced that our financing solution will provide the Group with the flexibility to pursue its future development.”

Ralph Hefti, MedEuropa’s CEO, commented: “Ardian’s ability to offer a flexible solution to the Group’s requirements was key to this partnership. Ardian has been extremely responsive and creative and has set up financing that is perfectly suited to the way MedEuropa intends to move forward.”

Nils Hagerstål, Vice President at Telemos Capital concluded: ”MedEuropa is actively considering further acquisition opportunities in the radiotherapy market, with the aim of building a platform in Western Europe. This ambitious development strategy demands a solid yet flexible financing solution, which Ardian has successfully provided.”

ABOUT CCO PERPIGNAN

 The CCO Perpignan center is located in Perpignan, in the South of France. It focuses on radiotherapy treatments through the operation of linear accelerators, treating a total 1,800 patients. It also provides some chemotherapy treatments in a more limited manner. CCO Perpignan enjoys a strong local reputation in the Pyrenées-Orientales region, and is known for providing high quality treatments to patients.

ABOUT MEDEUROPA

 Founded in 2017, MedEuropa is committed to providing state of the art cancer treatment across Europe, with a strong focus on radiotherapy. MedEuropa seeks to partner with leading medical professionals, who share its vision of improving the provision and quality of cancer treatment.  MedEuropa is pursuing an ambitious buy and build strategy, focusing on new partnership and acquisition opportunities across Europe.

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$96bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 640 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1,000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.

ABOUT TELEMOS CAPITAL

Telemos Capital invests in private European businesses, with the aim of building great companies for the long term. Funded by family capital, it combines the flexibility and nimble decision-making of a family office with the active ownership and professionalism of private equity. Telemos looks to deploy €50m-€200m of equity per investment and seeks to acquire majority stakes in businesses with the potential for sustainable growth through international expansion, add-on acquisitions or operational improvements.

LIST OF PARTIES INVOLVED

MedEuropa: Ralph Hefti, Raffael Kabir
Telemos Capital: Philippe Jacobs, Jacob Polny, Nils Hagerstål, Dipesh Mahtani
Ardian Private Debt: Guillaume Chinardet, Jean-David Ponsin, Gabrielle Philip

Financing Legal Advisor (Telemos Capital): Willkie Farr & Gallagher – Paul Lombard, Mathilde de Wiljes
Financing Legal Advisor (Ardian): Allen & Overy – Jean-Christophe David, Marine Tarditi, Adrien Repiquet

PRESS CONTACTS

ARDIAN
Headland
VIKTOR TSVETANOV

Categories: News

Tags: